ARMI | BioFabUSA is pleased to announce that it is co-sponsoring Worcester Polytechnic Institute’s 3rd Annual Advanced Biomanufacturing Symposium on April 9-10, 2018. The two-day event will focus on Advancements in Protein Therapeutics and Emerging Technologies as well as Cell and Tissue Therapies. Attendees of this conference will not only hear from industry leaders about advancements in the field and emerging technologies but will also have multiple opportunities for networking with various exhibitors at the event.
ARMI | BioFabUSA speakers include Chief Regulatory Officer Richard McFarland, who will be participating in a panel discussion titled “Regulatory Issues and Driving the Cost of Biologics Down”, and Chief Technology Officer Tom Bollenbach, who will be addressing attendees in a separate panel discussion titled “Recent Approaches for Cell and Tissue Therapy Process Development”.
We hope that you will join us at this event where WPI opens its doors to share its curricula, facilities and expertise, as well as discussing and learning how the biomanufacturing community can more effectively engage industry partners to increase the real-world focus on educational programs. Programs at the Biomanufacturing Education and Training Center (BETC) are available to industry employees as well as students at WPI and provides participants with hands-on training and exposes them to real-world scenarios that effectively prepares them as they get ready for a career in biomanufacturing.
Kamal Rashid, Research Professor in the Biology/Biotechnology Department and Director of the BETC, has helped to organize the upcoming event at WPI. Rashid, who has over thirty-five years of academic experience in both research and Biotechnology Education program development, has a research emphasis in several areas including in vitro mutagenesis and DNA repair studies in microbial and mammalian systems, molecular mechanism of chemical mutagenesis, structure-activity relationships with polycyclic aromatic hydrocarbons, and recombinant protein production in mammalian cell systems including Vero cells and recombinant CHO cell lines.
Kamal was kind enough to share his thoughts with us regarding what he hopes the event will allow the industry to achieve: “Today we are in the midst of a dramatic expansion and technological transformation of the Biomanufacturing industry world-wide. It is an exciting time for those who work in Biomanufacturing protein therapeutics, cell and tissue therapies and for physicians and patients who look to this industry to deliver new therapies that will ease suffering and cure disease. This year together with ARMI | BioFabUSA as a co-organizer of the symposium, we will engage in impactful discussions that translate into progress for the Biomanufacturing industry in the region.”
Click here to learn more about this event or to register – we look forward to seeing you there!